biological source
synthetic
assay
≥97.0% (N)
form
powder
optical activity
[α]20/D −77±2°, c = 1% in ethanol
mp
181-183 °C
SMILES string
OC(=O)c1ccccc1O.CNC(=O)Oc2ccc3N(C)[C@H]4N(C)CC[C@@]4(C)c3c2
InChI
1S/C15H21N3O2.C7H6O3/c1-15-7-8-17(3)13(15)18(4)12-6-5-10(9-11(12)15)20-14(19)16-2;8-6-4-2-1-3-5(6)7(9)10/h5-6,9,13H,7-8H2,1-4H3,(H,16,19);1-4,8H,(H,9,10)/t13-,15+;/m1./s1
InChI key
HZOTZTANVBDFOF-PBCQUBLHSA-N
Biochem/physiol Actions
乙酰胆碱酯酶抑制剂越过血脑屏障并与乙酰胆碱酯酶形成缓慢降解的氨基甲酰酶络合物。
wgk
WGK 3
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 2 Inhalation - Acute Tox. 2 Oral
存储类别
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges
法规信息
新产品
此项目有
S Rubnov et al.
Journal of pharmaceutical and biomedical analysis, 18(6), 939-945 (1999-01-30)
A simple stability-indicating HPLC assay has been developed for physostigmine salicylate, capable of following its degradation. A 250 x 5 mm i.d. column packed with 10 microm Bondapak C18 was used, with a mobile phase of acetonitrile - ammonium acetate
D K Lim et al.
Pharmacology, biochemistry, and behavior, 31(3), 627-631 (1988-11-01)
The present study demonstrates that continuous administration with physostigmine salicylate (0.12 or 0.24 mg/kg/hr via mini-osmotic pumps) induces toxicities (e.g., body weight loss, decreased water consumption, tremors, decreased body temperatures, mortality) in guinea pigs. Both blood and brain cholinesterase activity
F H Norris et al.
Clinical pharmacology and therapeutics, 54(6), 680-682 (1993-12-01)
We evaluated a double-blind, placebo-controlled, and double-crossover trial of oral physostigmine salicylate for a 9-month period in 13 of 25 patients with sporadic amyotrophic lateral sclerosis (ALS). A large dropout rate of 48% was secondary to eight deaths and four
